{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:32:48Z","timestamp":1708389168096},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,19]]},"DOI":"10.7759\/cureus.54453","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T11:03:07Z","timestamp":1708340587000},"source":"Crossref","is-referenced-by-count":0,"title":["Drug-Induced Liver Injury Secondary to Terbinafine Use"],"prefix":"10.7759","author":[{"given":"Aaron","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Potesta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajmal","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Terbinafine (systemic). Drug Information. (2021). Accessed: January 19, 2024: https:\/\/medilib.ir\/uptodate\/show\/9922."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.08.025","article-title":"Rhabdomyolysis attributed to terbinafine: a rare occurrence that can be mistaken for terbinafine-induced hepatotoxicity","volume":"5","author":"Ly P","year":"2019","unstructured":"Ly P, Subrt A, Wilkerson M. Rhabdomyolysis attributed to terbinafine: a rare occurrence that can be mistaken for terbinafine-induced hepatotoxicity. JAAD Case Rep. 2019, 5:47-9. 10.1016\/j.jdcr.2018.08.025","journal-title":"JAAD Case Rep"},{"key":"ref3","article-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Terbinafine [Internet]","year":"2012","unstructured":"LiverTox. Clinical and Research Information on Drug-Induced Liver Injury. Terbinafine [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2012."},{"key":"ref4","article-title":"Hepatotoxicity of antifungal agents","volume":"6","author":"Song JC","year":"2005","unstructured":"Song JC, Deresinski S. Hepatotoxicity of antifungal agents. Curr Opin Investig Drugs. 2005, 6:170-7.","journal-title":"Curr Opin Investig Drugs"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.202026","article-title":"Drug-induced liver injury","volume":"193","author":"Kumachev A","year":"2021","unstructured":"Kumachev A, Wu PE. Drug-induced liver injury. CMAJ. 2021, 193:E310. 10.1503\/cmaj.202026","journal-title":"CMAJ"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.08.004","article-title":"The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine","volume":"69","author":"Fontana RJ","year":"2018","unstructured":"Fontana RJ, Cirulli ET, Gu J, et al.. The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine. J Hepatol. 2018, 69:1317-25. 10.1016\/j.jhep.2018.08.004","journal-title":"J Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15854","article-title":"Clinical presentation of terbinafine-induced severe liver injury and the value of laboratory monitoring: a critically appraised topic","volume":"177","author":"Kramer ON","year":"2017","unstructured":"Kramer ON, Albrecht J. Clinical presentation of terbinafine-induced severe liver injury and the value of laboratory monitoring: a critically appraised topic. Br J Dermatol. 2017, 177:1279-84. 10.1111\/bjd.15854","journal-title":"Br J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50749","article-title":"Terbinafine-induced liver injury: a case report","volume":"15","author":"Jilani M","year":"2023","unstructured":"Jilani M, Zaidi S, Cazares Parson M, Brockman MJ, Hakim N, Edwards BP. Terbinafine-induced liver injury: a case report. Cureus. 2023, 15:e50749. 10.7759\/cureus.50749","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.1016\/S1665-2681(19)32159-3","article-title":"Terbinafine hepatotoxicity. A case report and review of literature","volume":"2","author":"Zapata Garrido AJ","year":"2003","unstructured":"Zapata Garrido AJ, Romo AC, Padilla FB. Terbinafine hepatotoxicity. A case report and review of literature. Ann Hepatol. 2003, 2:47-51.","journal-title":"Ann Hepatol"},{"key":"ref10","article-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Vanishing Bile Duct Syndrome [Internet]","year":"2012","unstructured":"LiverTox. Clinical and Research Information on Drug-Induced Liver Injury. Vanishing Bile Duct Syndrome [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2012."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21034","article-title":"Terbinafine-induced hepatic failure requiring liver transplantation","volume":"13","author":"Perveze Z","year":"2007","unstructured":"Perveze Z, Johnson MW, Rubin RA, et al.. Terbinafine-induced hepatic failure requiring liver transplantation. Liver Transpl. 2007, 13:162-4. 10.1002\/lt.21034","journal-title":"Liver Transpl"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/229016-drug-induced-liver-injury-secondary-to-terbinafine-use","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T11:03:12Z","timestamp":1708340592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/229016-drug-induced-liver-injury-secondary-to-terbinafine-use"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.54453","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,19]]}}}